Some bleeding risk scores have been proposed to predict MB (major bleeding) events in APE (acute pulmonary embolism) patients during anticoagulation therapy. Since patients who have undergone thrombolytic treatment are usually excluded from these studies, it is unknown whether these scores may provide an adequate prognostic value for in hospital major MB. Consequently, we evaluated some well-known bleeding scores to predict in hospital MB in APE patients who were treated with thrombolytic therapy.
Included in the retrospective study were 99 consecutive APE patients who had undergone thrombolytic therapy from June 2011 to August 2015. For each patient, we estimated bleeding risk using the Kuijer, Riete, Atria, Has-Bled, and Precise-Dapt scores.
In total, 22 MB events occurred in 99 (19%) patients following admission. A receiver operating characteristic curve analysis showed that the Precise-Dapt score might have an adequate prognostic value for MB (area under curve (AUC) value: 0.770). Meanwhile, the other abovementioned risk scores had poor predictive values (AUC values: 0.6120.658) for MB.
Despite being developed and validated to determine MB in patients receiving dual anti-platelet treatment, the Precise-Dapt score may be a useful system to estimate the risk of MB in APE patients who have undergone thrombolytic therapy.